First-of-Its-Kind National Online Survey Uncovers Obstacles to Comprehensive Healthcare for People With Sch... (rom variousgeographic regions and worked...)

First-of-Its-Kind National Online Survey Uncovers Obstacles to Comprehensive Healthcare for People With Schizophrenia

Date:1/29/2008

rom various geographic regions and worked in public, private and integrated health settings. The margin of error for the survey is 6.2%.

The survey was funded by an unrestricted educational grant from Solvay Pharmaceuticals and Wyeth Pharmaceuticals and by an anonymous individual donation.

For more information on the "Communicating About Health" survey, visit http://www.mentalhealthamerica.net/go/surveys or call Mental Health America of San Diego County at 619-543-0412.

About Mental Health America of San Diego County

Mental Health America of San Diego County is the county's oldest nonprofit dedicated to helping all people live mentally healthier lives. As part of a national organization with more than 320 affiliates nationwide, we represent a growing movement of Americans who promote mental wellness for the health and well-being of the nation - everyday and in times of crisis.

(i) Regier DA, Narrow WE, Rae DS, et al. The de facto USmental and addictive disorders service system. Epidemiologic catchment area prospective 1-year prevalence rates of disorders and services. Arch Gen Psychiatry. 1993;50:85-94.

(ii) Rose, L, Families of psychiatric patients: A critical review and future research directions. Archives of Psychiatric Nursing, 1996; 10(2), 67-76.

(iii) American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Text revision. Washington, DC: American Psychiatric Publishing. 2000;297-312.

(iv) Rosenheck R, Cramer J, Jurgis G, et al. Clinical and psychopharmacologic factors influencing family burden in refractory schizophrenia. J Clin Psychiatry. 2000;61:671-676.

(v) Wu EQ, Birnbaum HG, Shi L, et al. The economic burden of schizophrenia in the United States in 2002. J Clin Psych. 2005;66(9):1122-1129.

SOURCE Mental Health America of San Diego
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4
Related medicine news :

1. First-of-Its-Kind National Survey Uncovers Obstacles to Comprehensive Healthcare for People With Schizophrenia
2. Benefitfocus(R) Unwraps First-of-Its-Kind Healthcare Media Studio
3. TriWest Creates First-of-its-Kind Partnership to Offer Military Leaders With Grief Support Program
4. The American Nurses Association Hosts Conference on the National Database of Nursing Quality Indicators
5. National Institutes of Health funds new center for reproduction and infertility research at Illinois
6. National Business Coalition on Health Convenes Multi-Stakeholder Leadership Group to Address Value Based Purchasing Trends
7. Volunteer for National Suicide Prevention Agency Earns Cargill Award
8. February is National Pet Dental Health Month
9. MEDai Client Named Recipient of 2007 Malcolm Baldrige National Quality Award
10. AHIMA Launches National PHR Consumer Awareness Campaign
11. Senior Citizens Bureau Empowers Todays Seniors: National Non-profit Serves as Community Resource for Seniors, Their Children, Caregivers and Even Advocates

Post Your Comments:

(Date:11/24/2009)...Researchers at Ben-Gurion University of the Negev ... skin tumors, including melanomas that aren,t visi...the OSPI instrument (Optical Spectro-Polarimetric ...e never been seen before - including melanoma in p...ns and were awaiting surgery for their removal. Th...

(Date:11/24/2009)...Mid-Winter Meetings Jan. 27Feb. 2, 2010, at the Al...his year, SNM joins its annual Mid-Winter Educatio...cational Symposium of the American College of Nucl...r Imaging Summit and the Clinical Trials Network C...icipants an outstanding range of scientific conten...

(Date:11/24/2009)...sed sevenfold, study finds, , , TUESDAY...c-resistant infections normally found in the commu...tpatients, raising the risk that inpatients could ... to 2006, researchers found a sevenfold increase i...sistant Staphylococcus aureus (MRSA) infections....

(Date:11/24/2009)...ice to be coupled with Stem Cell Therapy. , ...24, 2009 -- Entest Biomedical, Inc. (OTCBB: ENTB... a manufacturer of lasers regarding the developmen...ed by Entest and used in conjunction with several ...ntest. These therapies are aimed at increasing eff...

(Date:11/24/2009)...o Get a Leg Up From the American Podiatric Medical...Md. (Vocus) November 24, 2009 -- The average perso... that number dramatically increases during the hol...continue making their holiday travel plans, it&rsq...runt of aches and pains while on the road. , , , ...

Breaking Medicine News(10 mins):Health News:New device enables early detection of cancerous skin tumors -- Ben Gurion U. 2 Health News:SNM's Conjoint Mid-Winter Meetings offer 4 scientific meetings in 1 location 2 Health News:MRSA Creeping Into Hospitals From the Outside 2 Health News:MRSA Creeping Into Hospitals From the Outside 3 Health News:Entest Biomedical Enters into Discussions with Laser Manufacturer to Develop Proprietary Photoceutical Device for COPD Treatment 2 Health News:Keep Holiday Travel Foot-Friendly 2 Health News:Keep Holiday Travel Foot-Friendly 3

[0] New device enables early detection of cancerous skin tumors -- Ben Gurion U.[0] SNM's Conjoint Mid-Winter Meetings offer 4 scientific meetings in 1 location [0] MRSA Creeping Into Hospitals From the Outside [0] Entest Biomedical Enters into Discussions with Laser Manufacturer to Develop Proprietary Photoceutical Device for COPD Treatment [0] Keep Holiday Travel Foot-Friendly

...egarding the outbreak of the deadly Rift valley Fe...warned against consumption of raw milk. // ...en borderline areas, is safe from the viral livest...due to hygienic concerns but also due to the fact ...

...linois at Chicago study published in the January i...ority of fertility clinic Web sites does not adher...nes. The study also found that services offer... offer financial incentives. Many consumers re...

...ts that doctors should advise and persuade patient...heir partners and bring// them for check up and tr...g kits or drugs in order to help reduce infection ...ransmitted infections often makes this difficult. ...

...ency, Pharmac, is in the process of doing away wit... Pharmac intends to phase out the ‘Aropax’ brand ... ‘Loxamine’. It is estimated that Aropax is used b...e, except for the appearance and the packaging. Fu...

...ake Forest University Baptist Medical Center are h...lving 83 other sites that will test 3,000 patients... is good for heart failure patients. Though d...he group of patients who primarily have heart fail...

... we shed tears. But exactly what our tears are mad... A new study sheds some light on the complex desig...call tear film, which is made up of three distinct...layer of fatty, oily substances collectively calle...

Other Medicine News:Health News:Experts Warn Against Raw Milk Following Rift Valley Fever Outbreak in Kenya 2 Health News:Experts Warn Against Raw Milk Following Rift Valley Fever Outbreak in Kenya 3 Health News:Fertility Clinic Web Sites Doesn’t Adhere to Ad-Guideline 2 Health News:New International Study to Test Exercise in Heart Failure Patients 2 Health News:New International Study to Test Exercise in Heart Failure Patients 3 Health News:Tears Reveal Some of Their Deepest Secrets to Researchers 2 Health News:Tears Reveal Some of Their Deepest Secrets to Researchers 3

Experts Warn Against Raw Milk Following Rift Valley Fever Outbreak in Kenya Fertility Clinic Web Sites Doesn’t Adhere to Ad-Guideline Doctors Role in Preventing STD Pharmac to Phase Out Aropax, Well-known Antidepressant New International Study to Test Exercise in Heart Failure Patients Tears Reveal Some of Their Deepest Secrets to Researchers

(Date:11/24/2009)...,Nov.24/PRNewswire-Asia/--HuifengBio-Pharmaceutica...eveloperandproducer,ofplantextractsandpharmaceutic...landfoodproductioninXi,an,China,todayreportedthati...revenues. , RevenuesforthequarterendedSept.30...om$3,534,623forthesamequarterin2008.Netincome,amou...

(Date:11/24/2009)...OOD,Calif.,Nov.24/PRNewswire-FirstCall/--IPCTheHos...alhospitalistphysiciangrouppracticecompany,announc...t,wasnamedby ACPHospitalist asoneofthe2009TopTenHo...2009issueofthemagazine. ,, Dr.Vaidyanhasbeenapr...vesasdirectorofhospitalmedicineatSt.Mary,sHealthCe...

(Date:11/24/2009)...,Nov.24/PRNewswire-FirstCall/--ZimmerHoldings,Inc....atinginthe21stAnnualPiperJaffrayHealthCareConferen...ternTime. ,, Alivewebcastofthepresentationcanbe...://investor.zimmer.com .Thewebcastwillbearchivedfo...any ,, Foundedin1927andheadquarteredinWarsaw,I...

Breaking Medicine Technology:Huifeng Bio-Pharmaceutical Technology Reports 26% Quarterly Revenue Increase 2 Huifeng Bio-Pharmaceutical Technology Reports 26% Quarterly Revenue Increase 3 IPC The Hospitalist Company's Philip Vaidyan, M.D. Named a Top Hospitalist of 2009 2 Watson Pharmaceuticals Resumes Shipment of INFeD 28R 29 28Iron Dextran Injection USP 29 51309 1 Watson Pharmaceuticals Resumes Shipment of INFeD 28R 29 28Iron Dextran Injection USP 29 51309 2 Watson Pharmaceuticals Resumes Shipment of INFeD 28R 29 28Iron Dextran Injection USP 29 51309 3 Connectyx Looks to Establish Market Leadership with MedSync and MedFlash Product Line As Stated During Nationwide Teleconference 51307 1 Connectyx Looks to Establish Market Leadership with MedSync and MedFlash Product Line As Stated During Nationwide Teleconference 51307 2 Connectyx Looks to Establish Market Leadership with MedSync and MedFlash Product Line As Stated During Nationwide Teleconference 51307 3 Bioniche Life Sciences Inc and Endo Pharmaceuticals Sign Licensing Agreement for Urocidin 28TM 29 4712 1 Bioniche Life Sciences Inc and Endo Pharmaceuticals Sign Licensing Agreement for Urocidin 28TM 29 4712 2 Bioniche Life Sciences Inc and Endo Pharmaceuticals Sign Licensing Agreement for Urocidin 28TM 29 4712 3 Bioniche Life Sciences Inc and Endo Pharmaceuticals Sign Licensing Agreement for Urocidin 28TM 29 4712 4 Bioniche Life Sciences Inc and Endo Pharmaceuticals Sign Licensing Agreement for Urocidin 28TM 29 4712 5 Bioniche Life Sciences Inc and Endo Pharmaceuticals Sign Licensing Agreement for Urocidin 28TM 29 4712 6

[0] Huifeng Bio-Pharmaceutical Technology Reports 26% Quarterly Revenue Increase [0] IPC The Hospitalist Company's Philip Vaidyan, M.D. Named a Top Hospitalist of 2009 [0] Zimmer Holdings to Present at 21st Annual Piper Jaffray Health Care Conference

...lood pressure reductions of 30.8 mm Hg,systolic bl...pressure (DBP),at five weeks and 21.1/19.3 mm Hg (... of patients with severe hypertension, AVAL...4.6 mm Hg (SBP/DBP), at 8 weeks, and 22.1/11.6 mm...ectively for irbesartan and HCTZ alone, in a study...

...Proprietary siRNA Molecule in Acute .... 19 Quark Pharmaceuticals, Inc., a,development-s... and,developing novel RNA interference-based thera...temic dosing in humans of its proprietary product,... developed by Quark for,the treatment of Acute Ren...

Other Medicine Technology:Powerful New Efficacy Data in Moderate and Severe Hypertensive Patients Supports FDA Approval of AVALIDE(R) (Irbesartan-Hydrochlorothiazide) as the First Combination Therapy for Initial Use in Patients Likely to Need Multiple Drugs to Achieve Their Blood 2 Powerful New Efficacy Data in Moderate and Severe Hypertensive Patients Supports FDA Approval of AVALIDE(R) (Irbesartan-Hydrochlorothiazide) as the First Combination Therapy for Initial Use in Patients Likely to Need Multiple Drugs to Achieve Their Blood 3 Powerful New Efficacy Data in Moderate and Severe Hypertensive Patients Supports FDA Approval of AVALIDE(R) (Irbesartan-Hydrochlorothiazide) as the First Combination Therapy for Initial Use in Patients Likely to Need Multiple Drugs to Achieve Their Blood 4 Powerful New Efficacy Data in Moderate and Severe Hypertensive Patients Supports FDA Approval of AVALIDE(R) (Irbesartan-Hydrochlorothiazide) as the First Combination Therapy for Initial Use in Patients Likely to Need Multiple Drugs to Achieve Their Blood 5 Powerful New Efficacy Data in Moderate and Severe Hypertensive Patients Supports FDA Approval of AVALIDE(R) (Irbesartan-Hydrochlorothiazide) as the First Combination Therapy for Initial Use in Patients Likely to Need Multiple Drugs to Achieve Their Blood 6 Powerful New Efficacy Data in Moderate and Severe Hypertensive Patients Supports FDA Approval of AVALIDE(R) (Irbesartan-Hydrochlorothiazide) as the First Combination Therapy for Initial Use in Patients Likely to Need Multiple Drugs to Achieve Their Blood 7 Quark Pharmaceuticals, Inc. Announces First Systemic siRNA Dosing in Humans 2 Quark Pharmaceuticals, Inc. Announces First Systemic siRNA Dosing in Humans 3 Quark Pharmaceuticals, Inc. Announces First Systemic siRNA Dosing in Humans 4

Powerful New Efficacy Data in Moderate and Severe Hypertensive Patients Supports FDA Approval of AVALIDE(R) (Irbesartan-Hydrochlorothiazide) as the First Combination Therapy for Initial Use in Patients Likely to Need Multiple Drugs to Achieve Their Blood Quark Pharmaceuticals, Inc. Announces First Systemic siRNA Dosing in Humans

Schepens Depressor 8.0mm Wide Tip Thimble Size 12

Yavitz Flap Cover

Chayett Drainage Ring

Weck-Cel Points

Medicine Products:

Schepens Depressor 8.0mm Wide Tip Thimble Size 12 Yavitz Flap Cover Chayett Drainage Ring Weck-Cel Points

First-of-Its-Kind National Online Survey Uncovers Obstacles to Comprehensive Healthcare for People With Sch...(rom variousgeographic regions and worked...),Health